Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : J&J warns of hit from generic drugs in third quarter, shares fall

07/16/2019 | 12:36pm EDT
The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

(Reuters) - Johnson & Johnson on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.

While J&J's pharmaceuticals unit has in recent years cushioned the impact of relatively slow growth in the company's medical device and consumer units, some of its older drugs have been hurt by competition from cheaper copies.

"We expect the largest impacts from generics and biosimilars for the year in our pharmaceutical business to occur in the third quarter," Chief Financial Officer Joseph Wolk said on a conference call.

Once a drug begins facing competition from multiple generic versions, it can quickly lose more than 80% of sales.

Sales of prostate cancer treatment Zytiga fell 23% in the quarter, hurt by generic copies, and sales of J&J's blockbuster arthritis drug Remicade fell 16%, impacted by biosimilar rivals.

Also weighing on the stock was the company's decision to not raise its full-year earnings forecast, even as sales across all its business units largely beat analysts' estimates.

"We expect questions on the maintained earnings per share guidance but we point to the continued-to-be-improving strength across its franchises despite pharma headwinds," said BMO Capital Markets analyst Joanne Wuensch.

Pharmaceutical sales in the quarter rose 1.7% to $10.53 billion, above analysts' estimates of $10.27 billion, according to three analysts polled by Refinitiv.

a graphic on 'J&J's newer drugs fuel pharmaceuticals unit sales' clickhttps://tmsnrt.rs/2kbwYl2

The company raised its 2019 forecast for operational sales, which excludes the impact of currency fluctuations, to a range of $82.4 billion to $83.2 billion, from a prior range of $82 billion to $82.8 billion.

J&J took a $190 million charge in the quarter related to litigation over its talc products. Executives on the conference call said this only related to defense costs and did not include liability payments.

The company faces lawsuits https://www.reuters.com/article/us-johnson-johnson-talc-probe/johnson-johnson-faces-criminal-probe-related-to-baby-powder-bloomberg-idUSKCN1U726J involving over 14,000 plaintiffs who allege use of its talc products, including Baby Powder, caused cancer https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer. J&J repeatedly has claimed its talc products are safe and that decades of studies have shown them to be asbestos-free and that they do not cause cancer.

Excluding items, the company earned $2.58 per share, beating analysts' expectations for $2.46 per share, according to IBES data from Refinitiv.

Sales fell 1.3% to $20.56 billion as growth in the international market helped counter falling sales in the United States. Analysts were expecting sales of $20.29 billion.

(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru and Julie Steenhuysen in Chicago; Editing by Bernadette Baum)

By Manas Mishra and Manojna Maddipatla

ę Reuters 2019
All news about JOHNSON & JOHNSON
04:09aASPEN PHARMACARE : To Send First Batch Of Johnson & Johnson Jab To South Africa ..
07/23Relaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $183 From $1..
07/23ASTRAZENECA : EU On Track To Donate 200 Million COVID-19 Vaccine Doses In 2021
07/22JOHNSON & JOHNSON : Opioid-ravaged West Virginia looks to $26B deal for help
07/22JOHNSON & JOHNSON : In opioid-ravaged WVa, potential deal raises hopes for help
07/22JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the..
07/22JOHNSON & JOHNSON : Covid-19 Vaccines - Current Challenge Is Not Supply but Usin..
07/21CARDINAL HEALTH : States reach $26B opioid settlement with Johnson & Johnson, 'b..
More news
Financials (USD)
Sales 2021 94 447 M - -
Net income 2021 22 808 M - -
Net Debt 2021 871 M - -
P/E ratio 2021 20,2x
Yield 2021 2,40%
Capitalization 452 B 452 B -
EV / Sales 2021 4,80x
EV / Sales 2022 4,58x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 171,79 $
Average target price 184,35 $
Spread / Average Target 7,31%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
NOVARTIS AG1.10%207 246
ABBVIE INC.10.30%199 548